Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results

Reuters

06/30

Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results

Cassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2547093296"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547093296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547093296?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547093296","market":"nz","top_or_hot":-1,"title":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-30 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL7PJhPg:1","article_id":"2547093296","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547093296","pubTimestamp":1751281229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results. Cassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex . The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.Disclaimer: This news brief was created by Public Tec","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","NDAQ":"纳斯达克OMX交易所"},"translate_title":"在取得有希望的临床前结果后，Cassava Sciences宣布计划对Simufilam治疗结节性硬化症相关癫痫进行临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SAVA":0.9},"content_text":"Cassava Sciences Announces Plans for Clinical Study of Simufilam in Tuberous Sclerosis Complex-Related Epilepsy, Following Promising Preclinical Results\n    \n\nCassava Sciences Inc. recently announced the presentation of promising preclinical data for simufilam, a small molecule treatment, at the TSC International Research Conference held in Bethesda, MD. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of focal onset seizures associated with Tuberous Sclerosis Complex (TSC). The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for TSC-related epilepsy. Earlier human Phase 3 studies in Alzheimer's disease involving 1,929 patients indicated a favorable safety profile for simufilam. The company is conducting additional preclinical studies to further explore simufilam's mechanism of action and potential benefits for TSC-related epilepsy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486469-en) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}